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Summary
Deficiency of glycogen phosphorylase in the liver gives
rise to glycogen-storage disease type VI (Hers disease;
MIM 232700). We report the identification of the first
mutations in PYGL, the gene encoding the liver isoform
of glycogen phosphorylase, in three patients with Hers
disease. These are two splice-site mutations and twomis-
sense mutations. A mutation of the 5′ splice-site consen-
sus of intron 14 causes the retention of intron 14 and
the utilization of two illegitimate 5′ splice sites, whereas
a mutation of the 3′ splice-site consensus of intron 4
causes the skipping of exon 5. Two missense mutations,
N338S and N376K, both cause nonconservative replace-
ments of amino acids that are absolutely conserved even
in yeast and bacterial phosphorylases. We also report
corrections of the PYGL coding sequence, sequence
polymorphisms, and a partial PYGL gene structure with
introns in the same positions as in PYGM, the gene of
the muscle isoform of phosphorylase. Our findings dem-
onstrate that PYGL mutations cause Hers disease, and
they may improve laboratory diagnosis of deficiencies
of the liver phosphorylase system.
Introduction
Glycogen phosphorylase catalyzes the degradation of
glycogen to glucose-1-phosphate by the phosphorylytic
cleavage of a-1,4-glycosidic bonds. In concert with de-
branching enzyme, phosphorylase is crucial for the util-
ization of glycogen as a storage form of glucose in vir-
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tually all animal cells. Glycogen is most abundant in the
liver, where it serves as a buffer reservoir of glucose units
for the maintenance of constant blood-glucose levels,
and in muscle, where it can be rapidly broken down to
provide energy for contraction. Phosphorylase activity
is regulated by various allosteric ligands and through
phosphorylation by phosphorylase kinase, which, in
turn, is controlled by neural and hormonal signals. Three
phosphorylase isoforms are known—the muscle (M),
liver (L) and brain (B) isoforms. They are encoded by
separate genesPYGM, PYGL, and PYGB, respec-
tively—which have been mapped to chromosomes 11,
14, and 20, respectively. The existence of isoforms with
distinct regulatory properties probably reflects the dif-
ferent functional roles and modes of regulation of gly-
cogen metabolism in different cell types (Crerar et al.
1995, and references therein).
Heritable deficiencies of phosphorylase cause glyco-
gen-storage disease (Chen and Burchell 1995). A defect
of the muscle isoform underlies glycogenosis type V
(McArdle disease), which, in most cases, is characterized
by exercise intolerance (early fatigue, pain, and cramps
on exertion) and juvenile to adult onset of symptoms.
Numerous mutations in PYGM have been identified in
recent years (Bartram et al. 1995; Vorgerd et al. 1998;
also see references in the latter). Phosphorylase defi-
ciency in the liver (glycogenosis type VI; Hers disease
[Hers 1959]; MIM 232700) manifests in infants, pri-
marily with hepatomegaly and growth retardation. It
typically takes a benign course, with remission of symp-
toms as the children grow up. No mutations underlying
liver phosphorylase deficiency have been reported.
Of the three isoforms of glycogen phosphorylase, ex-
pression of the L isoform seems to predominate in the
liver, both as protein and as mRNA (David and Crerar
1986; Newgard et al. 1988). Therefore, mutations in
PYGL would be suspected to be responsible for Hers
disease. Since liver phosphorylase deficiency can be dif-
ficult to diagnose biochemically and, in particular, dif-
ficult to differentiate from the much more common de-
ficiency of the activating enzyme, phosphorylase kinase,
mutation analysis may aid in the laboratory diagnosis
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of deficiencies of the liver phosphorylase system. The
present study identifies, for the first time, mutations in
PYGL in patients with liver phosphorylase deficiency.
Subjects, Material, and Methods
Patient 1 (BA.B), now 4 years 6 mo old, is the son of
Israeli Arab Bedouin parents who are first cousins. The
parents, four sisters, and two brothers are healthy. The
patient presented, at age 2 years, with hepatomegaly and
growth retardation (3d percentile) but had no clinical
history of fasting hypoglycemia. Serum transaminases,
triglycerides, and cholesterol were moderately elevated.
Total leukocyte phosphorylase activity was 12.5% of
that in a normal control, and phosphorylase a activity
was 11% of that in the control.
Patient 2 (SC.A) is the son of unrelated, healthy par-
ents of Suriname Hindustani ethnic background. He has
no siblings. Now 5 years 9 mo old, he presented, at age
2 years, with hepatomegaly and severe growth retar-
dation. Transaminases were intermittently elevated,
whereas plasma lipids were normal. Hypoglycemia was
measured after an 8-h fast. Severe glycogen storage in
hepatocytes was observed by both light microscopy and
electron microscopy. In a liver biopsy, moderately de-
creased activities were determined for total phospho-
rylase (13.5 mmol/min/g protein [control range 24–44
mmol/min/g protein]) and phosphorylase a (6 mmol/min/
g protein [control range 15–30 mmol/min/g protein]). In
erythrocytes, both activities were not significantly de-
creased. Phosphorylase kinase was normal, both in
erythrocytes and in liver.
Patient 3 (TS.M), now 3 years 4 mo old, is the daugh-
ter of consanguineous Turkish parents. At age 1 year
she presented with hepatomegaly. Body length was at
the 50th percentile, and weight was at the 10th percen-
tile. Transaminases, triglycerides, and cholesterol were
elevated. In a liver biopsy, glycogen was strongly ele-
vated (15% [normal range 2%–6%]), whereas border-
line low values were determined for total phosphorylase
(22 mmol/min/g protein [normal range 20–110 mmol/
min/g protein]) and phosphorylase a (9 mmol/min/g pro-
tein [normal range 10–50 mmol/min/g protein]). Liver
phosphorylase kinase was also low (1 mmol/min/g pro-
tein [normal 3–30 mmol/min/g protein]). Total phospho-
rylase and phosphorylase a in leukocytes were in the
normal range, as were glycogen and phosphorylase ki-
nase in erythrocytes.
Total RNA and genomic DNA were purified from fro-
zen whole blood by conventional methods, and ampli-
fication and direct sequencing were performed as de-
scribed in detail elsewhere (Burwinkel et al. 1996). For
PCR between different exons of PYGL, the long-tem-
plate PCR system of Boehringer Mannheim was em-
ployed. Glycogen phosphorylase activity was deter-
mined according to the method of Lederer et al. (1975)
and Lederer and Stalmans (1976).
Results
Mutations in PYGL, in Three Patients
Since the structure of PYGL has not been determined,
we based our mutation search on the amplification of
the PYGL coding sequence (Newgard et al. 1986), in
four overlapping intervals (A–D), by reverse transcrip-
tase–PCR (RT-PCR), from RNA isolated from whole
blood. PCR products were analyzed by direct sequenc-
ing, which employed the amplification primers and ad-
ditional sequencing primers (table 1).
Patient 1 is the son of consanguineous parents and
was therefore suspected to be homozygous for a single
mutation. RT-PCR of RNA from this patient yielded an
aberrant pattern of three bands, instead of one, in in-
terval D (fig. 1). Sequencing showed that the main,
longer-than-normal PCR product contains an insert of
119 nucleotides (nt) in codon R589, resulting in a frame-
shift and introducing a stop codon after five missense
codons. The minor band at the bottom represents a de-
letion of 67 nt that reaches from codon V567 to R589
and that also causes a frameshift (fig. 2). The band in
the middle represents the heteroduplex of these two
products, plus a third sequence with a 36-nt insertion,
in codon R589, containing an in-frame stop codon. In
PYGM, there is a short intron—intron 14—of 265 nt,
in the position corresponding to codon R589 (Burke et
al. 1987). We suspected that the exon-intron architecture
of PYGL is similar and could amplify, with primers LP7
and LP11 (table 1 and fig. 3)—which, by analogy with
PYGM, are predicted to lie in exons 14 and 15, respec-
tively—the corresponding gene segments from genomic
DNA of the patient and a normal control. Sequencing
showed that the patient’s insert is indeed an intron, pre-
sumably intron 14, but with a GrA replacement in the
GT consensus dinucleotide of the 5′ splice site (figs. 2
and 3). This splice-site mutation thus leads to the reten-
tion of intron 14 (the main product, the top band) and
two aberrant splice products employing neighboring GT
dinucleotides (doubly underlined in fig. 3) in exon 14
and in intron 14, respectively, as illegitimate 5′ splice
sites. Both parents were confirmed to be heterozygous
for the mutation.
RT-PCR of RNA of patient 2, who had no known
parental consanguinity, produced an aberrant band pat-
tern in interval B, displaying a normal-sized top band
and two additional bands below (fig. 1). The top band
represents the full-length sequence, whereas the bottom
band results from an in-frame deletion of 132 nt (44
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Table 1
Primers for Amplification and Analysis of the PYGL Coding Sequence
PCR Interval Primer Position (Direction) Sequence
RT-PCR:
A LP1 51 (r) 5′-CCG CAC TTC CAG CTC TCT G-3′
A LP2 559 (R) 5′-CAT ATC TGA GCC AAT CAT CTG-3′
B LP3 476 (r) 5′-GCA TTC GGT ATG AAT ATG GGA-3′
B LP4 1124 (R) 5′-TAG GCG AAG GTC TTC TGG TT-3′
C LP5 1038 (r) 5′-GAT CCC TGA GCT GAT GAG G-3′
C LP6 1704 (R) 5′-CAC CTG GAC ATC AAA CAT GG-3′
D/E LP7 1628 (r) 5′-AGC TGA AGT TTT CTC AGT TCC-3′
D LP8 2592 (R) 5′-ATG TTC AAG TTC AGT AAG AAG C-3′
S LP9 2109 (r) 5′-AGC TGG GGA AGA GAA CCT G-3′
S LP10 2188 (R) 5′-TTG CCT CGT ACC CTT TCT TG-3′
Gene analysis:
E (intron 14) LP11 1825 (R) 5′-TAC CAC CAA TGA TAA CTG TCC-3′
F (intron 5) LP12 741 (R) 5′-AGC AGA CCA GAG GCG CAT G-3′
F LP13 594 (r) 5′-GCT GCC TGT GCA CTT CTA TG-3′
G (intron 4) LP14 660 (R) 5′-TTG AGT GTC AAT CCA CTT GG-3′
G LP15 456 (r) 5′-ACT TGC AGC CTA TGG ATA CG-3′
S LPi1 Exon 5–116 (r) 5′-CAG TAT TCA TAA GTT GTT TCA G-3′
Figure 1 RT-PCR products indicating aberrant mRNA pro-
cessing due to splice-site mutations in patients 1 and 2. Sequence in-
tervals B and D were amplified from RNAs of patients 1–3, and the
products were resolved by agarose gel electrophoresis and were stained
with ethidium bromide. The central lane carries a 100-nt molecular-
size ladder (top band; 1,000 nt).
codons) between codons Q175 and V220 (fig. 2); the
middle band is a heteroduplex of the top and bottom
bands. The deletion corresponds to exon 5 of PYGM.
Therefore, we again suspected a splice-site mutation and
could amplify the PYGL region between putative exons
4 and 6 from normal genomic DNA, although intron 4
proved to be 110,000 nt long (fig. 3), as opposed to only
327 nt in PYGM. We then amplified and sequenced the
corresponding regions from the DNA of patient 2. His
sequences around the 5′ end of intron 4 and both ends
of intron 5 were normal, whereas he was heterozygous
for a GrC substitution in the AG consensus of the 3′
splice site of intron 4, which causes the skipping of exon
5 (figs. 2 and 3). The only other sequence abnormalities
in the PYGL coding sequence of patient 2 were a V221I
missense mutation and a N338S missense mutation,
both also in interval B. The sequence of the normal-sized
RT-PCR product of interval B (fig. 1) is homogeneous
for these two replacements, whereas the short RT-PCR
product of interval B, lacking exon 5, has normal V221
and N338 codons (also see the legend to fig. 2). From
this, we conclude that the splice-site mutation and the
two missense mutations are on separate alleles, although
parental samples were not available for analysis, and
that together they account for the patient’s enzyme de-
ficiency. The finding that the full-length splice product
represents exclusively the allele with the point mutations
also indicates that the splice-site mutation on the other
allele is fully abortive and allows no notable background
of normal transcript splicing. Codon N338 is absolutely
conserved in all three isoforms of glycogen phospho-
rylase and even in plant, yeast, and bacterial phospho-
rylases (fig. 2). The N338S mutation is therefore very
likely the second disease mutation. The V221I replace-
ment is a conservative substitution; valine 221 is con-
served in mammalian and yeast phosphorylases but, in
phosphorylases from slime mold, potato, and Escheri-
chia coli, is replaced by isoleucine, leucine, or methionine
(Hudson et al. 1993). This sequence variant may there-
fore be a polymorphism, and it is listed as such in table
2.
Patient 3 is the daughter of consanguineous parents.
The only sequence abnormality in her entire PYGL cod-
ing sequence is an apparently homozygous N376K mis-
sense mutation. N376 is absolutely conserved in the
Figure 2 Identification of PYGL mutations in patients 1–3. The left column shows the sequencing electropherograms documenting the
mutations. Triangles denote insertions or deletions; asterisks (*) denote nucleotide replacements; and arrowheads indicate where sequences have
to be read in complementary fashion from right to left. On the right, normal and mutant sequences are shown in comparison, with mutant
sequence positions highlighted in boldface type and shaded. Patients 1 and 3 are homozygous for their respective mutations. The two mutant
alleles of patient 2 give homogeneous sequences if determined from RT-PCR products, because both lie in interval B, so that the RT-PCR
products derived from the two alleles have different lengths and are separated by electrophoresis before being sequenced (fig. 1). Amplified
from genomic DNA, the splice-site mutation (mut 1) of patient 2 is seen together with the normal nucleotide of the second allele in this position.
Numbering of exons and introns is tentative, by analogy with the numbering of corresponding exons in PYGM. The GT dinucleotide in exon
14 (underlined) in patient 1 serves as an illegitimate 5′ splice site. The third aberrant-splicing product of patient 1, employing a GT in intron
14 (see fig. 3), is not illustrated. For the missense mutations of patients 2 and 3, high phylogenetic conservation of the mutated amino acids is
illustrated by alignment of corresponding partial sequences from the three human glycogen phosphorylase isoforms, from yeast glycogen
phosphorylase, and from both E. coli glycogen phosphorylase and maltodextrin phosphorylase. The sequences are taken from the work of
Hudson et al. (1993), where an alignment with additional phosphorylase sequences from slime mold and potato (N338 and N376 being
conserved also in these species) and an assignment of sequence positions to crystal structural features can also be found.
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Figure 3 Partial structure of the human PYGL. Exons are denoted by uppercase letters, and introns are denoted by lowercase letters.
Primers LP15, LPi1, LP13, LP14, LP12, LP7, and LP11 (from top to bottom), which were employed for amplification and sequencing, are
underlined. The g residues that are mutated at the end of intron 4 and at the beginning of intron 14, in patients 2 and 1, respectively, are
highlighted in boldface type. The GT dinucleotides in exon 14 and intron 14 that function as illegitimate 5′ splice sites in patient 1 are doubly
underlined. Nucleotide numbering and amino acid numbering refer to the cDNA sequence. The sequences have been submitted to the database
(accession numbers Y15229–Y15232).
three mammalian phosphorylase isoforms and also in
plant, yeast, and bacterial phosphorylases and is there-
fore a convincing deficiency mutation (fig. 2).
Partial PYGL Structure
As described above, parts of the human PYGL, be-
tween exons 4 and 6 and between exons 14 and 15,
could be amplified and sequenced directly from genomic
DNA (fig. 3). Introns 4 and 14 are found in positions
precisely corresponding to those of PYGM. Intron 5 is
shifted upstream in phase, by 1 nt, in PYGL, relative to
PYGM. Similarly precise conservation of intron posi-
tions but variation of intron lengths has been observed
between the genes of other protein isoforms (e.g., see
Aperlo et al. 1996; Burwinkel et al. 1998). These ob-
servations suggest that the rest of PYGL also will be
accessible for mutation analysis in an analogous way.
Corrected PYGL cDNA Sequence and Identification of
Polymorphisms
In all seven PYGL chromosomes analyzed by us, 13
codons of the PYGL coding sequence differed from the
published cDNA sequence (table 2). Three nucleotide
replacements are synonymous, but the others imply
changes in the encoded amino acids. In most of these
instances, the amino acids predicted by our sequence are
identical or more similar to their counterparts in the M
and B isoforms than are those in the published cDNA
sequence (table 2). Therefore, we believe that the se-
quence determined by us is the correct one, and we have
submitted it to the GenBank/EMBL sequence database
(accession number Y15233). In four other codons, we
have found single-nucleotide replacements between dif-
ferent chromosomes, three of them synonymous and one
causing a conservative amino acid substitution, and we
believe them to be polymorphisms (table 2).
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Table 2
Sequence Corrections and Polymorphisms in the PYGL
Coding Sequence
A. Amino Acid Replacements
in All Seven Chromosomes Analyzed
Amino Acid
Replacement
Nucleotide
Replacement
Corresponding Amino Acids
in M/B Phosphorylase
Gly1Ala GGCrGCG Ser/Gly
Glu2Lys GAArAAG Arg/Glu
Glu82Val GAArGTA Ile/Ile
Glu230Val GAGrGTG Val/Val
Gln322Ala CAArGCA Val/Val
Arg343Ala CGCrGCA Ser/Ala
Ile344Leu ATCrCTC Leu/Leu
Asn368Thr AACrACC Thr/Thr
Pro424Arg CCTrCGT Arg/Arg
Ser714Arg AGCrAGG Arg/Arg
B. Synonymous Nucleotide Replacements
in All Seven Chromosomes Analyzed
Amino Acid
Affected
Nucleotide
Replacement
Corresponding Codons
in M/B Phosphorylase
Pro3 CCGrCCC CCC/CCG
Thr5 ACArACG TCA/ACG
Arg60 CGGrCGC CGC/CGC
Polymorphisms
Asp50 GAC, six times GAT, once
Val221 GTC, six times ATC, once (Ile)
Asp339 GAT, twice GAC, five times
Thr671 ACC, twice ACT, five times
Discussion
In the present study, we have reported the identifi-
cation of the first mutations in PYGL, the gene encoding
the L isoform of glycogen phosphorylase, demonstrating
that PYGL is the gene responsible for glycogenosis type
VI (Hers disease). The splice-site mutation of patient 1
leads to three aberrant splicing products, all with a dis-
rupted reading frame. The splice-site mutation of patient
2 causes the in-frame deletion of a highly conserved seg-
ment of 44 amino acids, including sites implicated in
dimerization and glycogen binding (Hudson et al. 1993).
The two missense mutations both cause nonconservative
replacements of residues absolutely conserved between
mammals, plants, yeast, and bacteria. N338 is, accord-
ing to the crystal structure of muscle glycogen phos-
phorylase, buried in the interior of the protein, whereas
N376 is directly adjacent to the H377 residue implicated
in glucose interaction at the active site (Hudson et al.
1993). It still is possible that the mutant proteins affected
by the in-frame deletion and the missense mutations re-
tain some enzymatic activity, which might account for
the relatively high residual activity values measured in
the livers of patients 2 and 3. Background activity in the
liver, which also is seen in patient 1, may also be due
to coexpression of the B isoform (Newgard et al. 1988).
Mutation identification based on amplification of the
PYGL coding sequence from blood RNA or DNA may
help to improve the diagnosis of type VI glycogenosis.
Some laboratories find that it is difficult to determine,
by biochemical analysis, whether a defect in the liver
phosphorylase system is due to a deficiency of phos-
phorylase itself or to a deficiency of phosphorylase ki-
nase. This is attributed to the fact that phosphorylase
activity is influenced by multiple allosteric effectors and
humoral and neural signals that are difficult to control.
Moreover, phosphorylase kinase deficiency is typically
accompanied also by decreased total phosphorylase ac-
tivity (Lederer et al. 1975; Maire et al. 1991). Deter-
mination of phosphorylase activity can be performed in
leukocytes and other peripheral blood cells, but the L,
B, and M isoforms seem to be expressed in different
proportions in different blood cell types (Koster et al.
1976; Dahan et al. 1988), and details of blood-cell frac-
tionation may influence the possibility of detecting a
deficiency of the L isoenzyme (see data on patients 2
and 3, in the Subjects, Material, and Methods section
above). Some laboratories therefore consider it necessary
to perform a liver biopsy to establish the diagnosis, and
the possibility of being able to identify PYGL mutations
from blood RNA or DNA may help to avoid such
biopsies.
The biochemical data on patient 3 were ambiguous
because both phosphorylase and phosphorylase kinase
were low in a liver biopsy but were normal in blood
cells, and the patient was not available to allow us to
repeat the enzyme determinations. Since patient 3 is a
daughter of consanguineous parents, an autosomal
mode of inheritance was suspected, and the autosomal
phosphorylase kinase genes that can give rise to liver
glycogenosis—that is, PHKB and PHKG2 (Maichele et
al. 1996; Burwinkel et al. 1997a, 1997b, 1998; van den
Berg et al. 1997)—therefore were considered along with
PYGL. However, the entire PHKG2 coding sequence
and most of PHKB were analyzed, without any sequence
abnormalities being found, whereas a plausible N376K
missense mutation was found in PYGL. The example of
patient 3 thus illustrates that mutation analysis may sub-
stantiate a diagnosis of type VI glycogenosis when bi-
ochemical analysis remains insufficient.
A functional deficiency of glycogen phosphorylase in
the liver can be caused by mutations in four genes: either
in PYGL or in PHKB, PHKA2, or PHKG2—the genes
encoding, respectively, the b subunit and the L isoforms
of the a and g subunits of the activating enzyme, phos-
phorylase kinase. With the identification of PYGL mu-
tations, patients with mutations in any of these four
genes have now been described. Mutations in PHKA2,
PHKB, and PHKG2 produce similar clinical phenotypes
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and generally have a good prognosis (Kilimann 1997),
progression to cirrhosis being very rare and occurring
mainly in association with PHKG2 mutations (Burwin-
kel et al. 1998). The patients with PYGL mutations who
have been described here are clinically indistinguishable
from patients with liver phosphorylase kinase deficiency,
confirming that direct deficiency of phosphorylase does
not have more-severe functional consequences than
those produced by a deficiency of its regulatory protein
kinase.
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